Adjuvant chemotherapy for upper tract urothelial carcinoma
10.3760/cma.j.cn371439-20200227-00052
- VernacularTitle:上尿路上皮癌术后辅助化疗
- Author:
Mopei WANG
1
;
Liwen MA
Author Information
1. 北京大学第三医院肿瘤化疗与放射病科 100191
- From:
Journal of International Oncology
2020;47(7):436-439
- CountryChina
- Language:Chinese
-
Abstract:
Upper tract urothelial carcinoma (UTUC) patients have high recurrent rate and poor survival. Most of the previous studies of adjuvant chemotherapy in UTUC were retrospective and the results were controversial. Recent clinical trials support that adjuvant chemotherapy can improve disease-free survival of patients with locally advanced UTUC and platinum based regimens are standard adjuvant treatment. Currently the clinical trials results about effect comparison between adjuvant treatment and neoadjuvant treatment are limited. With the development of targeted therapy and immunotherapy, combinations with novel agents in the adjuvant setting might further improve the prognosis for locally advanced UTUC.
